Fractyl Health vs Profusa
GUTS and PFSA side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How GUTS and PFSA compare
Fractyl Health is the larger company, worth 11 times as much as Profusa ($12.0M against $1.1M).
Profusa scores higher on the StockData Score (4 against 1 for Fractyl Health), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | GUTS | PFSA |
|---|---|---|
| Size and price | ||
| Market cap | $12.0M | $1.1M |
| Share price | $0.904 | $0.448 |
| Change, 1 year | −93.3% | −100.0% |
| Beta (5Y) | 1.67 | 0.42 |
| Employees | 100 | – |
| StockData Score | ||
| Total score | 1 | 4 (better) |
| Valuation score | 0 | 1 (better) |
| Growth score | 0 | 0 |
| Performance score | 0 | 0 |
| Health score | 1 | 3 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/B | – | 0.1× |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Interest coverage | – | −174.1× |
| Current ratio | 1.98 (better) | 0.02 |
| Altman Z-score | −16.16 | −11.16 (better) |
| Piotroski F-score | 3 | 3 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 51.6% | 1.3% |
| Held by insiders | 66.1% | 52.3% |
| Insider net buying, 12 months | $187K (better) | −$116K |
| Short interest, % of float | 13.0% | – |
Go deeper
- GUTS stock overview
- GUTS income statement
- GUTS valuation and score
- PFSA stock overview
- PFSA income statement
- PFSA valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.